News
If you're a journalist with a media enquiry, please contact the Pfizer UK press office.
Please note that this route is intended for journalists with specific enquiries. We are unable to respond to any non-media enquiries submitted via this route.
Tel: 0845 300 8033
Email: [email protected]
PP-PFE-GBR-2513 / April 2020
-
MHRA grants temporary authorisation for Pfizer and BioNTech COVID-19 mRNA vaccine02/12/20 -
Sandwich Economic Impact Report Launched25/11/20 -
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints18/11/20 -
UPDATE: Albert Bourla discusses COVID-19 vaccine efficacy results09/11/20 -
An Open Letter from Pfizer Chairman and CEO Albert Bourla16/10/20 -
School children invited to take part in Superbugs: Join the Fight competition12/10/20 -
World Arthritis Day 202012/10/20 -
Biopharma Leaders Unite To Stand With Science09/09/20 -
Get the Facts on Our COVID-19 Vaccine Candidates07/08/20 -
Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance13/07/20 -
Pfizer and Wellcome Launch Surveillance Programme to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa07/07/20 -
And the winners are…‘Superbugs: Join the Fight’ school competition finalists announced07/07/20 -
Even Superheroes need a Sidekick29/06/20 -
Pfizer Establishes New Programme to Support Continued Biotechnology Innovation12/06/20 -
ByYourSide app and website launched to help cancer patients in need03/06/20 -
Pfizer and BioNTech Start Human Trials as Part of Global COVID-19 Vaccine Development Programme14/05/20